MUMBAI, India, Aug. 31 -- Intellectual Property India has published a patent application (202527111560 A) filed by Bluejay Therapeutics, Inc. on November 14, 2025, for Fusion Proteins Containing Il21 Muteins For Treating Cancer And Viral Diseases.
Inventors include Javanbakht, Hassan; Ramos, Hilario J.; Liu, Yue; Hoag, Matthew; and Wang, Bo.
The application for the patent was published on August 28, 2026, under issue no. 35/2026.
Abstract: A fusion protein includes an anti-PD1 antibody portion having a C-terminus, and an IL21 mutein conjugated with the anti-PD1 antibody portion with its C-terminus, wherein the IL21 mutein contains at least one of the two mutations relative to the wild-type IL21: (1) one of K72Y substitution, K72M substitution, and K72Q substitution, and (2) 75-80 deletion. In some examples, the anti- PD1 antibody can adopt a ETYY format, and can include a first heavy chain comprising a VH comprising a sequence of SEQ ID NO:11, and a second heavy chain comprising a VH comprising a sequence selected from the sequences of SEQ ID NOS:8-10. Pharmaceutical compositions including the fusion protein, nucleic acid coding the fusion protein, vectors including the nucleic acid, and methods of treating diseases using the fusion protein are also provided.
Disclaimer: Curated by HT Syndication.
